Terms: = Breast cancer AND STAT3, FLJ20882, 6774, ENSG00000168610, APRF, P40763, MGC16063 AND Clinical Outcome
13 results:
1. Long noncoding RNA HOST2, working as a competitive endogenous RNA, promotes stat3-mediated cell proliferation and migration via decoying of let-7b in triple-negative breast cancer.
Hua K; Deng X; Hu J; Ji C; Yu Y; Li J; Wang X; Fang L
J Exp Clin Cancer Res; 2020 Apr; 39(1):58. PubMed ID: 32248842
[TBL] [Abstract] [Full Text] [Related]
2. The Effect of a Newly Synthesized Ferrocene Derivative against MCF-7 breast cancer Cells and Spheroid Stem Cells through ROS Production and Inhibition of JAK2/stat3 Signaling Pathway.
Nourbakhsh M; Farzaneh S; Taghikhani A; Zarghi A; Noori S
Anticancer Agents Med Chem; 2020; 20(7):875-886. PubMed ID: 31893999
[TBL] [Abstract] [Full Text] [Related]
3. The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer.
Doherty MR; Parvani JG; Tamagno I; Junk DJ; Bryson BL; Cheon HJ; Stark GR; Jackson MW
Breast Cancer Res; 2019 Apr; 21(1):54. PubMed ID: 31036052
[TBL] [Abstract] [Full Text] [Related]
4. The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype.
Veenstra C; Karlsson E; Mirwani SM; Nordenskjöld B; Fornander T; Pérez-Tenorio G; Stål O
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1845-1856. PubMed ID: 31025094
[TBL] [Abstract] [Full Text] [Related]
5. Osthole inhibits triple negative breast cancer cells by suppressing stat3.
Dai X; Yin C; Zhang Y; Guo G; Zhao C; Wang O; Xiang Y; Zhang X; Liang G
J Exp Clin Cancer Res; 2018 Dec; 37(1):322. PubMed ID: 30577812
[TBL] [Abstract] [Full Text] [Related]
6. The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling: Implicating TIGAR in somatic resistance to endocrine therapy.
Fiorillo M; Sanchez-Alvarez R; Sotgia F; Lisanti MP
Aging (Albany NY); 2018 Dec; 10(12):4000-4023. PubMed ID: 30573703
[TBL] [Abstract] [Full Text] [Related]
7. Oct4 suppresses IR‑induced premature senescence in breast cancer cells through stat3- and NF‑κB-mediated IL‑24 production.
Kim JY; Kim JC; Lee JY; Park MJ
Int J Oncol; 2018 Jul; 53(1):47-58. PubMed ID: 29749438
[TBL] [Abstract] [Full Text] [Related]
8. 2-Phenylnaphthyridin-4-one Derivative LYF-11 Inhibits Interleukin-6-mediated Epithelial-to-Mesenchymal Transition
Liu LC; Wu YC; Kuo SC; Ho CT; Way TD; Chen ST
Anticancer Res; 2018 May; 38(5):2849-2859. PubMed ID: 29715108
[TBL] [Abstract] [Full Text] [Related]
9. Chemotherapy-Induced Ca
Lu H; Chen I; Shimoda LA; Park Y; Zhang C; Tran L; Zhang H; Semenza GL
Cell Rep; 2017 Feb; 18(8):1946-1957. PubMed ID: 28228260
[TBL] [Abstract] [Full Text] [Related]
10. Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of breast cancer Cells Influencing clinical outcomes.
Marusyk A; Tabassum DP; Janiszewska M; Place AE; Trinh A; Rozhok AI; Pyne S; Guerriero JL; Shu S; Ekram M; Ishkin A; Cahill DP; Nikolsky Y; Chan TA; Rimawi MF; Hilsenbeck S; Schiff R; Osborne KC; Letai A; Polyak K
Cancer Res; 2016 Nov; 76(22):6495-6506. PubMed ID: 27671678
[TBL] [Abstract] [Full Text] [Related]
11. stat3 and STAT5b polymorphism contributes to breast cancer risk and clinical outcomes.
Zhao L; Zhang Q; Luan X; Huang X; Zhao S; Zhao H
Int J Clin Exp Pathol; 2015; 8(2):2033-8. PubMed ID: 25973100
[TBL] [Abstract] [Full Text] [Related]
12. MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion.
Bockhorn J; Yee K; Chang YF; Prat A; Huo D; Nwachukwu C; Dalton R; Huang S; Swanson KE; Perou CM; Olopade OI; Clarke MF; Greene GL; Liu H
Breast Cancer Res Treat; 2013 Jan; 137(2):373-82. PubMed ID: 23224145
[TBL] [Abstract] [Full Text] [Related]
13. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells.
Sullivan NJ; Sasser AK; Axel AE; Vesuna F; Raman V; Ramirez N; Oberyszyn TM; Hall BM
Oncogene; 2009 Aug; 28(33):2940-7. PubMed ID: 19581928
[TBL] [Abstract] [Full Text] [Related]
